10 patents
Utility
Compositions and methods for the treatment and prevention of neurological disorders
8 Feb 22
The invention provides compositions and methods for treating neurological disorders, such as amyotrophic lateral sclerosis, frontotemporal degeneration, and Alzheimer's disease, among others.
Rebecca Aron, Bhaumik Pandya, Daniel Tardiff, Jeff Piotrowski, Matthew Lucas, Bertrand Le Bourdonnec, Kenneth Rhodes, Robert Scannevin
Filed: 21 Jun 19
Utility
Methods for the treatment of neurological disorders
13 Apr 21
The present disclosure provides compounds and methods useful in the treatment of neurological disorders.
Benjamin Vincent, Daniel Tardiff, Jeff Piotrowski, Eric Solis, Robert Scannevin, Chee-Yeun Chung, Rebecca Aron, Bertrand Le Bourdonnec, Matthew Lucas, Kenneth Rhodes
Filed: 5 Jan 18
Utility
Compounds and uses thereof
16 Feb 21
The present invention features compounds useful in the treatment of neurological disorders.
Iwona Wrona, Parcharee Tivitmahaisoon, Daniel Tardiff, Bhaumik Pandya, Kerem Ozboya, Matthew Lucas, Bertrand Le Bourdonnec
Filed: 24 Apr 19
Utility
Compounds, compositions, and methods for increasing CFTR activity
26 Jan 21
The present disclosure is directed to disclosed compounds that increase cystic fibrosis transmembrane conductance regulator (CFTR) activity as measured in human bronchial epithelial (hBE) cells.
Daniel Parks, Cecilia M. Bastos, Matthew Cullen, Benito Munoz
Filed: 21 Jun 17
Utility
Derivatives of 5-(hetero)arylpyrazol-3-carboxylic amide or 1-(hetero)aryltriazol-4-carboxylic amide useful for the treatment of inter alia cystic fibrosis
10 Aug 20
The present disclosure is based, in part, on the discovery that disclosed compounds such as those having Formula (IVa), (Va), (IV), or (V) can increase cystic fibrosis transmembrane conductance regulator (CFTR) activity as measured in human bronchial epithelial (hBE) cells.
Cecilia M. Bastos, Benito Munoz, Bradley Tait
Filed: 22 Dec 15
Utility
Compounds, compositions, and methods for increasing CFTR activity
10 Aug 20
The present disclosure features disclosed compounds which can increase cystic fibrosis transmembrane conductance regulator (CFTR) activity as measured in human bronchial epithelial (hBE) cells.
Cecilia M. Bastos, Benito Munoz, Bradley Tait
Filed: 13 Nov 18
Utility
Compounds, compositions, and methods for modulating CFTR
25 May 20
The present disclosure is directed to disclosed compounds that modulate e.g., address underlying defects in cellular processing of CFTR activity.
Benito Munoz, Daniel Parks, Cecilia M. Bastos
Filed: 6 Apr 17
Utility
Compounds, compositions, and methods of increasing CFTR activity
3 Feb 20
The present disclosure features compounds such as those having the Formulae (I) and (II), which can increase cystic fibrosis transmembrane conductance regulator (CFTR) activity as measured in human bronchial epithelial (hBE) cells.
Benito Munoz, Cecilia M. Bastos, John Miller
Filed: 24 Jul 16
Utility
Compounds, compositions, and methods for modulating CFTR
3 Feb 20
The present disclosure is directed to disclosed compounds that modulate, e.g., address underlying defects in cellular processing of CFTR activity.
Benito Munoz, Cecilia M. Bastos, Daniel Parks, David Kombo
Filed: 5 Oct 16
Utility
Proteostasis regulators
13 Jan 20
The present invention is directed to compounds having the Formulae (Ia-Ie), (II), (IIIa-IIId), (IVa-IVc), (Va-Vb), (VIa-VIe), (VII), (VIIIa-VIIIc), and (IX), pharmaceutically acceptable salts, prodrugs and solvates thereof, compositions of any of thereof and methods for the treatment of a condition associated with a dysfunction in proteostasis comprising an effective amount of these compounds.
Megan Foley, Bradley Tait, Matthew Cullen
Filed: 9 Jan 17
- Prev
- 1
- Next
Patents are sorted by USPTO publication date, most recent first